Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525628 · ClinicalTrials.gov registry record · Phase 1
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01525628 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 72 participants.
The verdict
NCT01525628, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
To evaluate the drug-drug interactions between BI 201335 and BI 207127 as well as their combined effect on CYP probe drug substrates and on tenofovir and raltegravir in treatment naive or prior treatment relapse patients with chronic hepatitis C infection.
Interventions
- DRUG midazolam
- DRUG tenofovir
- DRUG BI 201335
- DRUG caffeine
- DRUG tolbutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525628
The ClinicalTrials.gov registry entry for NCT01525628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which midazolam is the first listed.
NCT01525628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525628 about?
NCT01525628 is a clinical study titled "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients". To evaluate the drug-drug interactions between BI 201335 and BI 207127 as well as their combined effect on CYP probe drug substrates and on tenofovir and raltegravir in treatment naive or prior treatment relapse patients with chronic hepatitis C infection.
What is the current status of trial NCT01525628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2012-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01525628?
The interventions under investigation include: midazolam (DRUG), tenofovir (DRUG), BI 201335 (DRUG), caffeine (DRUG), tolbutamide (DRUG).
Who is sponsoring clinical trial NCT01525628?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.